Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

SHShunfeng HuBLBeibei Lv

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights enhanced efficacy and safety of antibody-drug conjugate in DLBCL, indicating potential for improved outcomes.

Key Points

  • Complete response rate reached 40.6% in DLBCL patients treated with polatuzumab vedotin-based regimens.
  • Progression-free survival significantly improved with full-course treatments, indicating better efficacy.
  • Assessment of adverse events revealed a safety profile consistent with mild toxicity, supporting tolerability.
  • Specific patient subgroups, such as elderly patients and those with high Ki67, showed enhanced treatment benefits.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d524https://doi.org/10.1182/blood-2025-7199
View Full Paper
Ask AI
Bookmark
Share